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Abstract
Objectives: To explore the possible role of n-3 polyunsaturated fatty acids (PUFAs) in lowering inflammation
markers in individuals with type 2 diabetes mellitus.
Methods: PubMed, CNKI and Cochrane databases were searched until December 30, 2015; references from papers
or reviews were also retrieved and screened. Screening was performed by two independent researchers, and
randomized controlled trials reporting the specific n-3 PUFA type, dose, frequency, and duration of treatment, as
well as the baseline and follow-up concentrations of inflammation markers, including interleukin 2 (IL-2), interleukin
6 (IL-6), tumor necrosis factor alpha (TNF-α) and C-reactive protein (CRP), were selected for final analysis. Data
analysis was performed using RevMan 5.2 software.
Results: Eight studies involving 955 participants were included; all reported CRP. Only one included study reported
IL-2 or IL-6 while two studies reported TNF-α. N-3 PUFAs significantly reduced CRP concentration compared with
control [SMD 95 % CI, 1.90 (0.64, 3.16), Z = 2.96, P = 0.003, random effect model].
Conclusions: N-3 PUFAs decrease CRP concentration in type-2 diabetes mellitus. However, larger and rigorously
designed RCTs are required to confirm this finding and extend it into other inflammatory biomarkers.
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Background
Diabetes is a major global health concern with an in-
creasing prevalence. It is estimated that by 2030, ap-
proximately 366 million adults will be diagnosed with
diabetes worldwide [1]. There is a considerable health
expenditure on the control of diabetes and the preven-
tion of its comorbidities. Both type 1 and type 2 diabetes
are associated with increased blood concentrations of
several inflammatory biomarkers, including C-reactive
protein (CRP), interleukin (IL)-2, IL-6 and tumour ne-
crosis factor-alpha (TNF-α) [2–4]. Such low-grade
inflammation, which may possibly be beneficial in the
early stage for promoting β-cell proliferation and insulin
production to compensate for insulin resistance, is the
mechanism underlying insulin resistance [5].
Although they are strongly linked to chronic low-
grade inflammation, diseases such as atherosclerosis,
type 2 diabetes mellitus (T2DM) and obesity are not
usually treated with anti-inflammatory pharmaceuticals.
However, it is thought that many dietary factors can in-
fluence various aspects of inflammation either promot-
ing or retarding specific inflammatory components [6].
Thus, nutrition may play a role in predisposing individ-
uals to conditions that have an inflammatory compo-
nent, and altered nutrition may be useful in preventing
or treating such conditions.
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Omega-3 (n-3) fatty acids are a family of polyunsatur-
ated fatty acids (PUFAs) that are characterized by the
position of a double bond in the hydrocarbon (acyl)
chain being between carbon numbers 3 and 4 counting
the terminal methyl carbon as number one. Longer
chain n-3 fatty acids include eicosapentaenoic acid (EPA;
20:5n-3), docosapentaenoic acid (DPA; 22:5n-3) and doc-
osahexaenoic acid (DHA; 22:6n-3) [7]. Epidemiological,
human intervention, animal and cell culture studies have
provided evidence supporting a beneficial role for dietary
n-3 PUFAs in many conditions associated with low-
grade chronic inflammation [6, 8–10]. N-3 PUFAs can
potentially decrease inflammation through several mech-
anisms, including inhibition of the arachidonic acid
(AA) pathway, inhibition of nuclear factor kappa B acti-
vation, and initiation of anti-inflammatory signalling
through G-protein coupled receptor 120 [11–13].
Whether n-3 PUFAs favorably affect biomarkers of in-
flammation in people with T2DM is not clear. Our aim
was to perform a systematic review and meta-analysis to




All English and Chinese language literature published
before December 30, 2015, was retrieved from PubMed,
China National Knowledge Infrastructure (CNKI), and
Cochrane library databases, and RCTs involving n-3
PUFAs and patients with T2DM were independently
screened for by two researchers. The following search
strategy was used:
# 1 ((“fatty acids”[MeSH Terms] OR (“fatty”[All Fields]
AND “acids”[All Fields]) OR “fatty acids”[All Fields]))
# 2 n3 [All Fields] AND #1
# 3 (“fatty acids, omega-3” [MeSH Terms] OR (“fatty”
[All Fields] AND “acids” [All Fields] AND “omega-3”
[All Fields]) OR “omega-3 fatty acids” [All Fields] OR
“omega 3 fatty acids” [All Fields])),
# 4 (“fish oils” [MeSH Terms] OR (“fish” [All Fields]
AND “oils” [All Fields]) OR “fish oils” [All Fields] OR
(“fish” [All Fields] AND “oil” [All Fields]) OR “fish oil”
[All Fields]),
# 5 “#2” OR “# 3” OR “# 4”,
# 6 (“inflammation” [MeSH Terms] OR “inflammation”
[All Fields]),
# 7 Clinical Trial [ptyp],
# 8 “#5” AND “# 6” AND “# 7”.
Titles and abstracts were obtained for selected articles.
Citation indices and reference lists of retrieved articles
were checked for additional studies that were not identi-
fied in the original database search.
Study selection
In phase 1, all papers retrieved by an independent
author were reviewed by at least two other authors who
independently selected the papers that they believed met
the inclusion criteria for full-text reading. In cases of
disagreement, the researchers discussed their different
assessments and reached a consensus. In phase 2, the
first author reviewed all full articles that met the eligibility
criteria. The following inclusion criteria were applied:
 a study should report the baseline and after-
treatment data for at least one inflammation
biomarker;
 all study subjects should be diagnosed or confirmed
with T2DM, with reported impaired fasting glucose;
 a control arm, with or without a placebo, should be
described.
After confirming the included literature, baseline and
post-treatment inflammation biomarker data were
selected and placed in a PICOS table that included the
author names, publication year, participant characteristics,
intervention and controlled arms, and n-3 PUFA dose, as
well as the control, baseline and end-point levels of each
reported inflammation biomarker.
Data collection and calculation
If the required data could not be directly gathered from
the paper, the corresponding author was contacted by
email to request these details. The Δ change value of any
inflammation marker equals the after-treatment value
minus the baseline value. Finally, the Δ change of the in-
flammation markers in the n-3 PUFA and control arms
were compared. If the Δ change value was reported in
the paper or as supplementary material, the data were
directly used for the analysis.
If a study reported inflammation markers at two or
more time points, for example at 12 and 16 weeks of
intervention, we regarded them as two subgroups.
Quality evaluation
Clinical trial bias and the quality of the literature were
evaluated by two independent researchers, according to
the Cochrane risk of bias guidelines [14], which included
random sequence generation, allocation concealment,
blinding of participants, personnel and outcome assessors,
incomplete outcome data, selective outcome reporting,
and other bias measurements (Additional file 2).
Statistical analysis
For continuous variables, the pooled effect was reported
as the standardized mean difference (SMD), with the
corresponding 95 % CI [15]. Heterogeneity was assessed
using I2 tests, and a p value of < 0.05 was considered to
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be significant. If heterogeneity was present, the pooled
effect size was calculated through a random-effects
model.
Results
Search results and study characteristics
We identified 3312 published papers from three data-
bases (Fig. 1). Review articles, viewpoints, editorials,
commentaries, and animal studies were excluded. Clin-
ical trials that did not provide data on the effect of n-3
PUFAs on any of the evaluated inflammation markers
were also excluded. According to the inclusion and ex-
clusion criteria, 8 RCTs [16–23] were selected for inclu-
sion (Fig. 1, Additional files 1 and 2). Reference papers
identified in other reviews of n-3 PUFAs and T2DM
were also retrieved, but none were included in the final
analysis. In total, data from 8 RCTs in T2DM were in-
cluded in the analysis.
Effect of N-3 PUFAs on inflammation markers
Eight RCTs were selected for the final analysis; these in-
cluded 955 participants (Table 1). In all eight studies the
age of all participants was over 18 y. The duration of n-3
PUFA intervention ranged from 6 to 12 weeks. Either
fish oil providing a mix of EPA and DHA or pure EPA
or DHA were used and in all studies these were pro-
vided in capsules. The minimum daily dose of n-3
PUFAs used was 1 g and the maximum was 6 g (Table 1).
Data for inflammation biomarkers from the eight in-
cluded studies are shown in Table 2.
A pooled analysis of the 8 included studies [16–23] en-
rolling 955 T2DM subjects revealed that the concentra-
tion of CRP was significantly decreased in the n-3 PUFA
group compared with the control group (SMD 1.90;
95 % CI, 0.64 to 3.16, p = 0.003; Fig. 2. The test for het-
erogeneity was significant (I2 = 98 %, p < 0.00001).
For a subgroup analysis, EPA and DHA were tested
separately (Fig. 3). Although the heterogeneity was sig-
nificant in both subgroups, the P values for the SMD in
each analysis were less than 0.05 indicating that both
EPA and DHA lower CRP concentration.
Only two trials reported data for TNF-α concentration.
Malekshahi Moghadam [17] found that n-3 PUFA intake
at 2.7 g/d significantly lowered TNF-α concentration
compared to sunflower oil as placebo. However, Mori
[19] reported that neither EPA nor DHA at 4 g/d low-
ered TNF-α concentration in early-stage T2DM patients.
Only one trial explored the effects of n-3 PUFAs on
IL-2 and IL-6 in T2DM [18, 19]. IL-2 concentration was
significantly decreased in T2DM subjects who under-
went an 8-week intervention with 2.7 g/d n-3 PUFAs.
No significant effect of n-3 PUFAs on IL-6 concentra-
tion was detected.
Discussion
The overall findings from this systematic review and
meta-analysis suggest that supplemental n-3 PUFAs can
lower CRP concentration in patients with T2DM, al-
though the heterogeneity was significant among the se-
lected studies. There were too few studies to evaluate
the effect of n-3 PUFAs on other inflammatory bio-
markers in T2DM to reach any clear conclusion.
CRP, along with IL-2, IL-6 and TNF-α, belongs to the
cluster of general inflammation markers identified in a
large variety of diseases and conditions. Clinically, CRP
has emerged as a leading inflammatory biomarker for
CVD [24] and, thus, has been of interest to researchers
studying the role of n-3 PUFAs in diabetes complica-
tions, a key CVD risk factor. Epidemiological studies
have assessed the relationship between CRP concentra-
tion and n-3 fatty acid intakes in healthy subjects and in
patients with coronary disease [24, 25], confirming an
inverse association and suggesting an anti-inflammatory
Fig. 1 Flow chart for selection of included studies
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Table 1 Characteristics of included studies regarding n-3 PUFA from any source and inflammation markers in T2DM













N-3 PUFA source Dose
(g/d)
Placebo Quality
Brinton 2013 [21] RCT T2DM USA 513/501 >18 12 Icosapent ethyl (EPA) 4, 2 placebo A
Azizi-Soleiman 2013 [16] RCT T2DM Iran 60/45 59.4 ± 8.2 12 EPA or DHA 1 Canola oil B
Lee 2014 [17] RCT Early-stage T2DM or MetS USA 80/59 57.9 8 EPA + DHA 6 Corn oil B
Malekshahi Moghadam
2012 [18]
RCT T2DM Iran 84/NA 45–85 (mean
54.2)
8 EPA + DHA 2.7 Sunflower
oil
B
Mori 2003 [19] RCT Treated-hypertensive T2DM Australia 59/51 61.2 ± 1.2 6 EPA or DHA 4 Olive oil C
Pooya 2008 [20] RCT T2DM Iran 90/81 45–85 (mean
54.5)
8 EPA + DHA 2.2 Sunflower
oil
B
Soleimani 2015 [23] RCT T2DM with diabetic
nephropathy (DN)
Iran 60/60 45–85 (mean
62.6)
12 Flaxseed oil (ALA) 1 placebo B
Wong 2015 [22] RCT T2DM without prior
cardiovasular disease
China 97/91 60 ± 9 (Mean
60.1)
12 Fish oil (42 % EPA
+25 % DHA)
4 Olive oil A















Table 2 Inflammation biomarkers pre- and post-intervention across included studies
Placebo N-3 PUFA
Inflammation biomarker Author/year n Pre-intervention Post-intervention n Pre-intervention Post-intervention P (vs placebo) Note
CRP (mg/l) Brinton 2013 [21] 165 2.50 ± 2.88 3.10 ± 3.48 165 2.50 ± 2.07 2.10 ± 2.52 NA 4 g/d EPA
165 2.50 ± 2.88 3.10 ± 3.48 171 2.10 ± 2.67 2.70 ± 2.52 NA 2 g/d EPA
Azizi-Soleiman 2013 [16] 17 2.15 ± 2.29 2.42 ± 2.49 14 2.20 ± 2.65 2.73 ± 3.45 NA EPA treatment
17 2.15 ± 2.29 2.42 ± 2.49 14 2.85 ± 3.58 2.18 ± 2.98 NA DHA treatment
Lee 2014 [17] 21 2.36 ± 0.57 3.72 ± 1.00 16 6.08 ± 3.19 3.59 ± 1.03 NA
Malekshahi Moghadam 2012 [18] 42 18.7 ± 16.8 18.2 ± 11.1 42 25.7 ± 27.4 20.4 ± 24.2 >0.05
Mori 2003 [19] 16 2.01 ± 0.57 2.12 ± 0.57 17 2.28 ± 0.55 2.02 ± 0.43 >0.05 EPA treatment
16 2.01 ± 0.57 2.12 ± 0.57 17 3.70 ± 0.61 3.84 ± 0.73 >0.05 DHA treatment
Pooya 2008 [20] 41 3.15 ± 0.36 3.80 ± 0.17 40 2.70 ± 0.02 2.48 ± 0.23 >0.05
Soleimani 2015 [23] 30 2.93 ± 0.45 2.56 ± 0.43 30 2.66 ± 0.51 2.42 ± 0.45 NA
Wong 2015 [22] 48 1.68 ± 2.53 1.28 ± 1.56 49 1.36 ± 1.43 1.71 ± 3.11 0.15 No adjustment for baseline value
TNF-α (pg/ml) Malekshahi Moghadam 2012 [18] 42 38.7 ± 9.53 40.6 ± 11.0 42 37.5 ± 6.41 34.5 ± 6.40 0.002
Mori 2003 [19] 16 15.35 (10.7–22.0) 14.26 (10.7–18.9) 17 24.44 (18.2–32.9) 19.67 (14.6–26.5) >0.05 EPA treatment
16 15.35 (10.7–22.0) 14.26 (10.7–18.9) 17 20.51 (14.7–28.6) 13.78 (9.50–19.9) >0.05 DHA treatment
IL-2 (pg/ml) Malekshahi Moghadam 2012 [18] 42 42.46 ± 19.78 51.52 ± 19.71 42 42.47 ± 13.85 35.25 ± 11.28 0.0001
IL-6 (pg/ml) Mori 2003 [19] 16 1.76 (1.39–2.23) 1.96 (1.57–2.45) 17 1.75 (1.40–2.20) 1.78 (1.54–2.06) >0.05 EPA treatment
16 1.76 (1.39–2.23) 1.96 (1.57–2.45) 17 2.22 (1.46–3.38) 2.15 (1.52–3.03) >0.05 DHA treatment















effect of n-3 PUFAs. EPA and DHA can both decrease
TNF-α levels and improve insulin resistance [26, 27]. In
Mori’s study, both EPA and DHA tended to decrease the
inflammatory marker TNF-α, although this did not
reach statistical significance [19]. In vitro and in vivo
studies of n-3 and n-6 fatty acids have revealed that
these fatty acid families could inhibit the production of
inflammatory cytokines, including IL-1, IL-2 and TNF-α,
by stimulated human lymphocytes [28]. EPA and DHA
were found to markedly lower IL-2 levels when incu-
bated with lymphocytes from diabetic patients or from
controls [29].
Although several studies support the idea that n-3
PUFAs can potentially lower inflammation markers, the
findings are inconsistent. There are several possible rea-
sons for this. First, the type of subjects studied varies
from trial to trial and n-3 PUFAs might be less effective
in some types of subject. For instance, one study found
that consumption of n-3 PUFAs did not affect the
plasma levels of CRP among individuals who suffer from
dyslipidaemia and obesity [30]. In contrast, another
study reported that 4 weeks of n-3 PUFA supplementation
lowered serum CRP levels in individuals with inflamma-
tory diseases by 93 % [31]. Secondly, dose-dependent ac-
tions of n-3 PUFAs on inflammatory responses have not
been well described, but it appears that a dose of at least
2 g/d is necessary to achieve an anti-inflammatory effect
[32]. Studies included in the current meta-analysis used a
variety of doses, some below the suggested anti-
inflammatory threshold. Thirdly, EPA and DHA may have
different effects and different studies have used different
mixtures of those two fatty acids. Azizi-Soleiman et al.
Fig. 3 Subgroup analysis of n-3 PUFA on CRP
Fig. 2 Forest plot for effect of n-3 PUFA on CRP concentration in all studies (random effect model)
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showed that 1 g/d of DHA but not EPA was able to lower
CRP concentration [16]. Fourthly, small patient cohorts,
short study durations and genetic variability may also
play roles in the inconsistencies. An individual’s gen-
etic background may affect the response to fish oil
supplementation. In Grimble’s study, SNPs at -308
and +252, respectively, of the TNF-α and LT-α genes
were found to influence the ability of fish oil (a source of
n-3 PUFAs) to suppress TNF-α production in a complex
manner [33].
In addition, circulating levels of CRP and IL-6 and also
of adiponectin are beneficially modulated by weight loss
and (or) exercise [34–36]. Studies of n-3 PUFA supple-
mentation tend not to consider body weight, BMI or/
and exercise or adjust for these factors as covariates
[37].
This current study has some limitations. First, the
number of included studies is low, which could give rise
to publication bias. Secondly, literature published only in
English or Chinese was considered, which may be a
selection bias.
Conclusions
In conclusion, this meta-analysis indicates that persons
with T2DM who received n-3 PUFA supplements had
significantly lower CRP levels compared with subjects in
control groups. However, the number and scale of the
included studies were small. Further carefully designed
RCTs are required to confirm this finding and extend it
into other inflammatory biomarkers.
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